Capecitabine tablets are a nucleoside metabolic inhibitor with antineoplastic activity. The body changes capecitabine into a common chemotherapy drug called fluorouracil. It stops cells making and repairing DNA. Capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine tablets in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.
Capecitabine tablets should be swallowed whole with water within 30 minutes after a meal.
HCPCS code: J8520, J8521 - Bar Code Information on each sell unit – AB bioequivalent oral
Storage and Handling: Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. KEEP TIGHTLY CLOSED. Capecitabine is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1Any unused product should be disposed of in accordance with local requirements, or drug take back program.